becton dickinson compani
lutonix btk approv may hing
summari follow fda advisori committe adcom meet
paclitaxel ptx coat peripher devic june weve
receiv number investor inquiri around likelihood
approv bdx lutonix drug-coat balloon dcb below-
the-kne btk indic compani file fda
lutonix current indic peripher arteri diseas pad
superfici femor arteri sfa above-the-kne atk
arterioven fistula avf access note walk
posit factor could lead approv lutonix btk
potenti risk approv btk continu believ
prudent exclud lutonix btk revenu model
given uncertainti around approv base summari
ptx adcom meet post fda websit think fda
decis btk approv like impact
lutonix btk data date seen btk efficaci data
six month continu assign less chanc
btk approv acknowledg tough call approv
btk could potenti contribut sale
would add bp bdx revenu growth
ep rais price target
base updat blend peer ev/ebitda
price-to-earnings valuat analysi
posit factor could lead approv lutonix btk
greater unmet need btk compar sfa/atk
fda execut summari recent ptx advisori committe
meet contain section btk indic fda summari
state current devic approv
btk pad despit rel high morbid mortal rate
patient fda goe state patient typic
multipl comorbid mortal rate within
month diagnosi mortal rate year
regardless treatment fda cite data swedish registri
collect data patient follow revascular
show approxim incid death
amput year
continu next page
pleas see page rate definit import disclosur
requir analyst certif estimates/forecast
well fargo secur llc seek busi compani
cover research report result investor awar
firm may conflict interest could affect object report
investor consid report singl factor make
compani data secur llc estim reuter
includ bcr acquisit start ep calcul use two method
determin impact prefer convert as-convert
compani data secur llc estim reuter
pivot lutonix btk trial show signific differ lutonix control
primari efficaci endpoint use kaplan-mei km analysi well clinic
driven target lesion revascular six month primari efficaci endpoint lutonix
btk trial composit limb salvag primari patenc pp six month defin
freedom composit ankl amput target vessel occlus clinic driven target
lesion revascular cd-tlr import note primari efficaci endpoint limb
salvag primari patenc differ lutonix arm control arm pta
percutan translumin angioplasti statist differ analyz use pre-
specifi statist method vs signific note despit valu less
press releas state differ statist signific believ
due interim analys data lower valu need achiev statist
signific known alpha penalti howev analyz primari efficaci
endpoint use differ statist analysi kaplan meier km differ lutonix
arm pta arm reach statist signific favor lutonix vs
addit statist signific differ lutonix pta cd-tlr six month
trend toward lower mortal lutonix arm versu control arm
pivot lutonix btk trial three year accord total random subject
dcb pta enrol pivot lutonix btk trial studi design follow-
month fda brief document recent ptx adcom state
subject evalu month overal death rate dcb pta
neg factor could lead non-approv lutonix btk
primari efficaci endpoint meet statist signific pivot us lutonix btk
trial mention primari endpoint lutonix btk trial composit limb salvag
primari patenc pp six month defin freedom composit ankl
amput target vessel occlus clinic driven target lesion revascular cd-tlr
primari efficaci endpoint limb salvag pp differ lutonix arm control
arm pta statist differ six month use pre-specifi statist method vs
primari efficaci endpoint analyz use differ
statist approach lutonix arm show signific differ pta arm
fda adcom appear suggest new indic need show efficaci
control arm month fda adcom ask chang studi design ptx coat
devic sfa atk indic accord summari meet post fda
websit panel agre fda continu approv devic clinic data
demonstr assur safeti effect fda strengthen post-approv
condit ensur adequ data collect potenti signal detect follow question
panel ask relev recommend indic ptx coat
devic summari goe state panel indic recommend
paclitaxel-co devic sfa also appli clinic studi inform consent label
paclitaxel-co devic use indic avf critic limb ischemia note
fda tend use btk interchang panel note benefit-risk profil
patient may differ given high mortal rate patient within year
present lutonix btk data month yet mention
primari endpoint pivot lutonix btk trial measur six month fda agre
chang endpoint month six month key question view
fda requir posit efficaci data given panel recommend
lutonix btk data look like month lutonix btk data favor versu pta
would expect fda approv lutonix btk convers data
different/favor versu pta month fda might reluct approv lutonix btk given
mortal signal identifi ptx coat devic given bcr request chang primari
endpoint six month month suggest us concern durabl
efficaci lutonix btk patient
mortal signal ptx coat devic rais bar approv new devic
indic believ bar approv new devic indic ptx coat devic
may higher mortal signal seen devic may caus fda reluct
expand usag devic clearer idea true mortal risk
implic btk regard market opportun btk
acquir bcr bcr estim btk opportun peak sale call
push btk approv previou assumpt approv chang result
becton dickinson compani
decreas sale guidanc impli see btk least
annual opportun like higher assum btk sale would add
bp revenu growth ep assum contribut
margin mention current includ btk lutonix estim
therefor approv repres potenti upsid forecast even without btk forecast
organ sale growth ep growth current trade
consensu ep discount larg cap med-tech median
price target
price target base blend ev/ebitda ebitda price-to-earnings
estim risk includ slower expect integr bcr lower expect cost save
accret bcr unexpect delay debt pay unexpect pipelin delay/setback
believ well posit acceler top- bottom-lin growth bcr acquisit
potenti upsid
global medic devic compani oper two key segment medic life
scienc pend bcr acquisit add third leg platform intervent grew
revenu nearli pro forma underli basi
